Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (SEHK:8329) entered into equity transfer agreement to acquire Shenzhen Neptunus Changjian Pharmaceutical Company Limited from Shenzhen Neptunus Yinhe Pharmaceutical Investment Company Limited and Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) for CNY 5.1 million on December 11, 2012. Shenzhen Neptunus Yinhe Pharmaceutical Investment will sell 70% stake and will receive CNY 3.56 million and Shenzhen Neptunus Bioengineering will sell 30% stake and will receive CNY 1.52 million. Upon completion, two sums of CNY 0.77 million and CNY 1.78 million will be paid to Shenzhen Neptunus Bioengineering and Shenzhen Neptunus Yinhe Pharmaceutical Investment respectively. Within one year from the date of completion, the remaining balance of CNY 0.75 million and CNY 1.78 million will be paid to Shenzhen Neptunus Bioengineering and Shenzhen Neptunus Yinhe Pharmaceutical Investment respectively.

As of November 30, 2012, Shenzhen Neptunus Changjian Pharmaceutical had total net assets of CNY 4.13 million. For the year ended December 31, 2011, Neptunus Changjian Pharmaceutical had net profits before taxation and extraordinary terms of CNY 7.96 million and net profits after taxation and extraordinary terms of CNY 5.72 million. The transaction is subject to due diligence, Shenzhen Neptunus Bioengineering having made disclosure and obtained approvals (if necessary) pursuant to the listing rules applicable to the securities listed on the Shenzhen Stock Exchange, and obtained approvals from the Shenzhen Stock Exchange or the CSRC or other authorized institutions (if necessary), stock exchange approval, approval of the Board of Directors and the shareholders of Shenzhen Neptunus Changjian Pharmaceutical Company, Shenzhen Neptunus Changjian Pharmaceutical having obtained a letter of approval from the Shenzhen Administration for Industry & Commerce and third party approval. The Board of Directors of Shenzhen Neptunus Interlong Bio-Technique considers that terms and conditions are fair and reasonable and are in the interests of Shenzhen Neptunus Interlong Bio-Technique and its shareholders as a whole. The transaction will be completed on January 4, 2013, failing which Shenzhen Neptunus Interlong Bio-Technique may either terminate the agreement or postpone completion to a later date but in any event not later than January 31, 2013.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (SEHK:8329) completed the acquisition of Shenzhen Neptunus Changjian Pharmaceutical Company Limited from Shenzhen Neptunus Yinhe Pharmaceutical Investment Company Limited and Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) on January 4, 2013.